Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3

Conditions

Prostatic Neoplasms 63Lymphoma, Large B-Cell, Diffuse 47Lymphoma 33Burkitt Lymphoma 27Lymphoma, Follicular 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 17Lymphoma, Non-Hodgkin 14Neoplasms 13Lymphoma, B-Cell 11Lymphoma, T-Cell, Peripheral 10Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 9Hodgkin Disease 9Lymphoma, B-Cell, Marginal Zone 8Leukemia 8Recurrence 6Prostatic Neoplasms, Castration-Resistant 6Multiple Myeloma 6Leukemia, Lymphocytic, Chronic, B-Cell 6Neoplasm Metastasis 5Leukemia, Biphenotypic, Acute 5Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoproliferative Disorders 4Lymphoma, T-Cell 4Lymphoma, Mantle-Cell 4Lymphoma, Large-Cell, Anaplastic 4Immunoblastic Lymphadenopathy 4Ovarian Neoplasms 3Myasthenia Gravis 3Melanoma 3Lymphoma, AIDS-Related 3

Interventions

pembrolizumab 137Nivolumab 116Ipilimumab 68Cyclophosphamide 33Specimen Handling 31Magnetic Resonance Spectroscopy 28trametinib 23binimetinib 22fludarabine 21Interleukin-2 20dabrafenib 19relatlimab 17encorafenib 17Biopsy 17CTLA-4 Antigen 16cemiplimab 15atezolizumab 15aldesleukin 15Radiosurgery 15fludarabine phosphate 14Opdualag 14Radiotherapy 11lenvatinib 10Blood Specimen Collection 10lifileucel 9Paclitaxel 8Cisplatin 8Bevacizumab 8spartalizumab 7cobimetinib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Melanoma × Prednisone × 1 year × Clear all
NCT05896839 2026-05-13

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

National Cancer Institute (NCI)

Phase 1/2 Recruiting
16 enrolled
Dermatologic

Carcinoma, Basal Cell, Melanoma, Carcinoma, Merkel Cell

NCT03816332 2026-04-30

Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers

National Cancer Institute (NCI)

Phase 1 Active not recruiting
12 enrolled 13 charts
Dermatologic

Carcinoma, Basal Cell, Melanoma, Carcinoma, Merkel Cell

NCT04305145 2026-01-29

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

Massachusetts General Hospital

Phase 2 Active not recruiting
42 enrolled
Dermatologic

Colitis, Melanoma, Skin Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡